Novan Appoints Tomoko Maeda-Chubachi, MD, PhD, MBA as Chief Medical Officer
August 24, 2021 09:00 ET
|
Novan, Inc.
– Dr. Maeda-Chubachi, who served as Novan’s Senior Vice President, Medical has played a key role in the design and execution of the Company’s development programs – – Dr. Maeda-Chubachi was...
Novan Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 12, 2021 07:05 ET
|
Novan, Inc.
– Positive data across all three of the Company’s priority pipeline development programs, announced in Q2 2021, further validating the potential of its novel, proprietary NITRICIL™ technology – –...
Novan to Report Second Quarter 2021 Financial Results on August 12, 2021
August 05, 2021 08:05 ET
|
Novan, Inc.
DURHAM, N.C., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its second quarter 2021 financial results on Thursday,...
Novan Announces Last Patient Visit at Week 24 in B-SIMPLE4 Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum
July 28, 2021 08:05 ET
|
Novan, Inc.
– Company previously reported positive topline efficacy and favorable safety data at Week 12 from B-SIMPLE4 in June 2021, with primary endpoint achieving statistical significance with p-value less...
Novan Announces Inclusion in Russell Microcap® Index
June 24, 2021 08:05 ET
|
Novan, Inc.
DURHAM, N.C., June 24, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that as part of the annual reconstitution of the Russell stock indexes, Novan...
Novan Announces Closing of $40 Million Public Offering of Common Stock
June 21, 2021 16:01 ET
|
Novan, Inc.
DURHAM, N.C., June 21, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company" or "Novan") (NASDAQ:NOVN) today announced the closing of the Company's previously announced underwritten public offering...
Novan Announces Pricing of $40 Million Public Offering of Common Stock
June 17, 2021 09:00 ET
|
Novan, Inc.
DURHAM, N.C., June 17, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company" or "Novan") (NASDAQ:NOVN) today announced the pricing of the Company's previously announced underwritten public offering...
Novan Announces Proposed Public Offering of Common Stock
June 16, 2021 16:01 ET
|
Novan, Inc.
DURHAM, N.C., June 16, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company” or “Novan”) (NASDAQ: NOVN) today announced a proposed underwritten public offering of its common stock (the “Offering”)....
Novan Reports Positive Topline Results from Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum
June 11, 2021 06:30 ET
|
Novan, Inc.
– B-SIMPLE4 achieves statistical significance for the primary endpoint with p-value less than 0.0001 – – No serious adverse events related to treatment with SB206 – – Novan intends to submit New...
Novan Announces Positive Preclinical Data in SB019 COVID-19 Anti-Viral Therapy Program
June 10, 2021 08:30 ET
|
Novan, Inc.
– Data indicate that berdazimer sodium prevents progression of SARS-CoV-2 infection in two independent in vivo transmission studies – – Statistically significant, dose-dependent reduction in the...